[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100119836":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":36,"centralContacts":27,"locations":40,"responsibleParty":54,"collaborators":27,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":27,"acronym":27,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":27,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":78,"whyStopped":27,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":27,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"A","EXPERIMENTAL","ABT-143 capsules 5\u002F45mg",[13],"Drug: ABT-143",{"label":15,"type":16,"description":17,"interventionNames":18},"B","ACTIVE_COMPARATOR","ABT-335 45mg and rosuvastatin 5mg",[19,20],"Drug: ABT-335","Drug: rosuvastatin",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","ABT-143","Once, please see Arm Description for more details.",[9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"ABT-335","Once, see Arm Description for more detail",[15],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"rosuvastatin","once, see Arm Description for more detail",[15],[37],{"name":38,"affiliation":5,"role":39},"Torbjörn Lundström, MD","STUDY_DIRECTOR",[41],{"facility":42,"status":27,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":27},"Site Reference ID\u002FInvestigator# 13441","Orlando","Florida","32809","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-81.37924,28.53834,{"lat":52,"lon":51},{"type":55,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100119836","phase-1-comparison-of-the-bioavailability-of-fenofibric-acid-and-rosuvastatin-from-545-mg-strength-of-abt-143-relative-to-that-from-the-coadministration-of-abt-335-fenofibric-acid-45-mg-and-rosuvastatin-calcium-5-mg-100119836",false,"NCT00826358","Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5\u002F45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg","Inclusion Criteria:\n\n1. A condition of general good health\n2. BMI 19 to 29\n\nExclusion Criteria:\n\n1. Currently enrolled in another clinical study\n2. Females who are pregnant or breast-feeding",true,"ALL","18 Years","55 Years",{"count":67,"type":68},90,"ACTUAL","INTERVENTIONAL",[71],"PHASE1","The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.",[74],"Healthy",[76,77],"Adverse events","Pharmacokinetic","COMPLETED","2012-09-27",{"date":81,"type":82},"2012-09-28","ESTIMATED",{"date":84,"type":27},"2008-11",{"name":5,"class":6},1]